OSI-774 definition

OSI-774 means the selective inhibitor of epidermal growth factor receptor having the IUPAC name [6,7-bis(2-methoxyethoxy)quinazolin-4-yl]-(3-ethynylphenyl)-amine and having the U.S. Approved Name erlotinib.
View Source

Examples of OSI-774 in a sentence

  • OSI has participated in the development of a certain molecule known as OSI-774 (defined below) and has certain intellectual property rights related thereto.

  • Additionally, as of the Effective Date, to its knowledge (without investigation), neither Party (i) has received notice from any Third Party that OSI-774 infringes on any patent or patent application owed by such Third Party that would have a material effect on the operations to be conducted by or on behalf of the Parties under this Agreement, or (ii) has received an adverse written legal opinion from competent outside patent counsel that has not been disclosed to the other Party.

  • During the development of OSI-774, each Party may transfer certain of its proprietary materials to the other Party.

  • To the extent that Lifecycle Initiatives put forward by the OSI-774 Liaison Team to the GDC have not been approved, such Lifecycle Initiatives shall be handled pursuant to Section 4.3A(b) below.

  • In addition, the Joint Project Team Leaders will participate in the OSI-774 Liaison Team, described in Section 3.4 below, to exchange information, and facilitate cooperation and coordination, between the Parties and Roche, pursuant to the Tripartite Agreement.

  • Pursuant to the terms of the Tripartite Agreement, the Parties have established with Genentech a Global Development Committee to, among other things, direct development of OSI-774.

  • Any member of the OSI-774 Liaison Team may designate a substitute to attend and ------------------- ** This portion has been redacted pursuant to a confidential treatment request.

  • The Parties have established the OSI-774 Liaison Team to liaise between the Roche Project Team and the OSI/Genentech Joint Project Team which will be composed of one representative of each Party (who should be the head of the applicable Project Team) who has been appointed by each Party (and may be replaced at any time by such Party) on written notice to the other Parties in accordance with this Agreement.

  • Each Party acknowledges that simultaneously with this Agreement, OSI will be entering into an agreement with Genentech regarding, among other things, development of OSI-774 outside the Territory.

  • In addition, the Parties and Genentech have established an OSI-774 Liaison Team to coordinate the development activities of the OSI-Genentech Project Team and the Roche Project Team as more fully described in the Tripartite Agreement.